Saghmos Therapeutics, Inc. (Saghmos), a privately owned biopharmaceutical firm, has disclosed its collaboration with the Duke Clinical Research Institute (DCRI) to enhance and strategize the implementation of Saghmos’ Phase 3…
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has unveiled encouraging two-year topline results from the ARCH trial. The ARCH study, conducted at a single…
Fresenius Kabi, a division of Fresenius, has launched Tyenne® (tocilizumab-aazg) in the U.S., a biosimilar of Actemra® (tocilizumab), approved by the FDA on March 5, 2024. Tyenne® is available in…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical firm focused on innovative treatments for spinal muscular atrophy and other serious conditions, announced granting inducement equity awards to two new employees. These…
The latest addition to ResearchAndMarkets.com’s offerings: Global Research Antibodies & Reagents Market Forecast 2024-2029. The Global Research Antibodies & Reagents Market witnessed a valuation of USD 13.39 billion in 2023,…
Today, TheracosBio announced the publication of a study in the Journal of Diabetes titled “Comparison of Bexagliflozin with Dapagliflozin as an Adjunct to Metformin in Chinese Patients with Type 2…
Today, Gennao Bio, a private genetic medicine enterprise pioneering targeted nucleic acid therapies, revealed fresh preclinical findings regarding the use of its non-viral, cell-penetrating gene monoclonal antibody (GMAB) platform technology.…
Today at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, Genialis, a leading RNA-biomarker company, unveiled their latest AI/ML classifier, Genialis™ krasID. This innovative tool…
Australian biotech firm, Ferronova, has commenced a clinical trial featuring their FerroTrace® nanoparticle technology in individuals diagnosed with gastric and esophageal cancers. This trial follows the successful completion of a…
Onchilles Pharma, a pioneering biotech firm specializing in cancer treatments harnessing a unique innate immune approach for targeted and potent tumor eradication, revealed groundbreaking preclinical findings today. The data pertained…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a prominent RNAi therapeutics firm, has unveiled encouraging outcomes from the KARDIA-2 Phase 2 trial. This study assessed the effectiveness and safety of a single…
Edgewood Oncology, a biotech company specializing in BTX-A51 treatments for hematologic malignancies and solid tumors, has revealed fresh preclinical findings. The study, conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah…